Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Stock analysts at Cantor Fitzgerald upped their FY2019 earnings estimates for shares of Zynerba Pharmaceuticals in a research report issued on Wednesday, March 13th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will earn ($2.22) per share for the year, up from their previous forecast of ($2.77). Cantor Fitzgerald currently has a “Buy” rating and a $11.00 target price on the stock.
Several other research analysts have also commented on ZYNE. ValuEngine lowered Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, January 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $13.38.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.21. The company had revenue of $0.09 million during the quarter.
A number of large investors have recently added to or reduced their stakes in ZYNE. Campbell Capital Management Inc. acquired a new position in Zynerba Pharmaceuticals during the 4th quarter worth approximately $510,000. Two Sigma Investments LP acquired a new position in Zynerba Pharmaceuticals during the 4th quarter worth approximately $120,000. BlackRock Inc. increased its position in Zynerba Pharmaceuticals by 0.9% during the 4th quarter. BlackRock Inc. now owns 300,949 shares of the company’s stock worth $893,000 after purchasing an additional 2,594 shares in the last quarter. Virtu Financial LLC acquired a new position in Zynerba Pharmaceuticals during the 4th quarter worth approximately $40,000. Finally, Vanguard Group Inc increased its position in Zynerba Pharmaceuticals by 23.8% during the 3rd quarter. Vanguard Group Inc now owns 651,400 shares of the company’s stock worth $5,316,000 after purchasing an additional 125,327 shares in the last quarter. 15.39% of the stock is currently owned by institutional investors.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Read More: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.